Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy

European Journal of Cancer

Volumn 46, Issue 5, 2010, Pages 937-943

  Sharpe, Katharine H ^a   McClements, Paula ^a   Clark, Douglas I ^a   Collins, Joanne ^a   Springbett, Anthea ^a   Brewster, David H ^a,b  

^a INFORMATION SERVICES DIVISION   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Breast neoplasm; Epidemiology; Hormone replacement therapy; Incidence; Mammography; Oestrogen receptor; Trends

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CLIMACTERIUM; FEMALE; GROUPS BY AGE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; UNITED KINGDOM;

AGED; BREAST NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MIDDLE AGED; PERIMENOPAUSE; POISSON DISTRIBUTION; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RISK FACTORS; SCOTLAND;

EID: 77349083670     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.01.003     Document Type: Article

References (36)

1. Brewster D.H., Sharpe K.H., Clark D.I., and Collins J. Declining breast cancer incidence and decreased HRT use. Lancet 373 (2009) 459-460
2. Information Services Division Scotland. Prescribing information system, dispensed items (extracted 27 August 2008).
3. Anon, and Million Women S.C. Breast cancer and hormone-replacement therapy in the million women study. Lancet 362 (2003) 419-427
4. Information Services Division Scotland. Scottish Cancer Registry [extracted August 2008].
5. Allemand H., Seradour B., Weill A., and Ricordeau P. Decline in breast cancer incidence in 2005 and 2006 in France. A paradoxical trend. Bull Cancer 95 (2008) 11-15
6. Bakken K., Lund E., and Eggen A.E. The impact of hormone replacement therapy on the incidence of breast cancer in Norway. J Clin Oncol 23 (2005) 3636-3637
7. Canfell K., Banks E., Moa A.M., and Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188 (2008) 641-644
8. Katalinic A., and Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107 (2008) 427-430
9. Kerlikowske K., Miglioretti D.L., Buist D.S.M., Walker R., and Carney P.A. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99 (2007) 1335-1339 [2007; 99:1335]
10. Kliewer E.V., Demers A.A., and Nugent Z.J. A decline in breast-cancer incidence. N Engl J Med 357 (2007) 509-510
11. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 372 (2008) 608-610
12. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
13. Anon, Office of National Statistics. Distribution of the European standard population; 1998; Available from: .
14. Scottish Executive Health Department. Scottish Health Survey 1998, vol. 1; 2000. p. 400.
15. Chen W.Y., Hankinson S.E., Schnitt S.J., et al. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101 (2004) 1490-1500
16. Glass A.G., Lacey J.V., Carreon J.D., and Hoover R.N. Re: breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status - response. J Natl Cancer Inst 99 (2007) 1152-1161
17. Anon, Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
18. Anon, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1484 [1997; 350:1047].
19. Olevsky O.M., and Martino S. Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women. Menopause 15 (2008) 790-796
20. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy - annual trends and response to recent evidence. JAMA 291 (2004) 47-53
21. Merrill R.M. Hysterectomy Surveillance in the United States 1997 through 2005. Med Sci Monit 14 (2008) CR24-CR31
22. Parkin D.M. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?. Eur J Cancer 45 (2009) 1649-1653
23. Information Services Division Scotland. Breast screening. [accessed 8 June 2009].
24. Khan H.N., Bendall S., and Bates T. Is hormone replacement therapy-related breast cancer more favorable? A case-control study. Breast J 13 (2007) 496-500
25. Soerjomataram I., Coebergh J.W.W., and Louwman W.J. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands?. J Clin Oncol (2007) 5038-5039
26. Cady B., Chung M.A., and Michaelson J.S. A decline in breast-cancer incidence. N Engl J Med 357 (2007) 511
27. Information Services Division Scotland. Trends in incidence. .
28. Warnberg F., Yuen J., and Holmberg L. Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 355 (2000) 724-725
29. Colditz G.A., Rosner B.A., Chen W.Y., Holmes M.D., and Hankinson S.E. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96 (2004) 218-228
30. Althuis M.D., Fergenbaum J.H., Garcia-Closas M., et al. Etiology of hormone receptor-defined breast cancer: a systematic review of' the literature. Cancer Epidemiol Biomarkers Prev 13 (2004) 1558-1568
31. Byers T., Trujillo S., and Hines L. Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 100 (2008) 596
32. Boyages, J. Organised mammography screening programmes: a positive perspective. Brit Med J Rapid Response 2009. Available from: http://www.bmj.com/cgi/eletters/339/jul09_1/b2587#216948.
33. Vitak B., Stal O., Manson J.C., et al. Interval cancers and cancers in non-attenders in the Ostergotland mammographic screening programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence. Eur J Cancer 33 (1997) 1453-1460
34. Porter P.L., El Bastawissi A.Y., Mandelson M.T., et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91 (1999) 2020-2028
35. Brewster D.H., and Stockton D.L. Ascertainment of breast cancer by the Scottish Cancer Registry: an assessment based on comparison with five independent breast cancer trials databases. Breast 17 (2008) 104-106
36. Brewster D.H., Stockton D., Harvey J., and Mackay M. Reliability of cancer registration data in Scotland, 1997. Eur J Cancer 38 (2002) 414-417